Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions - GBI Research Reports

Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions

Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions - GBI Research Reports
Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions
Published Dec 01, 2010
177 pages — Published Dec 01, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest report, 'Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs,Top Pharma Companies and Key Mergers and Acquisitions' that provides key data, information and analysis of the major trends and issues affecting the Pharmaceutical market. The report provides a comprehensive insight into the history of Pharmaceutical Industry Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions, its uses, efficiency as well as their limitations. The report also provides a detailed analysis of Pharmaceutical Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions in terms of its market size, and the major market drivers and barriers.. The report also looks into Pharmaceutical drug pipeline along with analysis on the pipeline by indication, phase of development and geography of development.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of the report includes:
- Detailed overview of pharmaceutical industry 2009-2010.
- Annualized market data
- Key market drivers and restraints, challenges and trends shaping the Pharmaceutical market
- Pipeline analysis of the along with segmentation by indication, phase and geography
- Competitive landscape analysis with competitive profiling of leading companies such as
- Analysis of M&A deals from 2009-2010 along with segmentation by value geography and companies

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Develop better strategies pharmaceutical industry
- Develop market-entry and market expansion strategies
- Understand the factors shaping the Pharmaceutical industry market
- Reinforce R&D pipeline
- Identify the key players best positioned to take the advantage of the opportunities in the pharmaceutical market
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

  
Source:
Document ID
GBIHC045MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents48
1.1 List of Tables91
1.2 List of Figures102
2 Introduction121
2.1 GBI Research Report Guidance121
3 Global Pharmaceutical Market Overview 2009134
3.1 Introduction131
Total Sales Of Pharmaceutical Drugs In 2009131
3.3 Market Share By Therapeutic Areas, 2009141
3.4 Top Selling Drugs Of 2009151
3.4.1 Lipitor (atorvastin)151
3.4.2 Plavix (clopidrogel)151
3.4.3 Nexium (esmoprazole)151
3.4.4 Advair (fluticasone salmetrol)151
3.4.5 Seroquel (quetiapine)151
3.4.6 Diovan (valsartan)151
3.4.7 Enbrel (etanercept)151
3.4.8 Remicade (infliximab)151
3.4.9 Crestor (rosuvastatin)151
3.4.10 Zyprexa (olanzapine)151
3.5 Key Patent Expirations Of Drugs In 2009161
4 Key Therapeutic Landscape1765
Cardiovascular Disease Therapeutics171
4.1.1 Drivers for Cardiovascular Therapeutics Market181
4.1.1.1 Increase In The Aging Population 191
4.1.1.2 Stable Increase In The Incidence Rates For Cardiovascular Disorders 191
4.1.1.3 Increase In The Diagnosis Rate Of The Disease 191
4.1.1.4 Increase In The Awareness Levels Of Disease Progression And Etiology 191
4.1.2 Restraints For Cardiovascular Therapeutics Market201
4.1.2.1 Patent Expiries Coupled With Generic Competition 201
4.1.2.2 Presence Of Serious Side Effects 201
4.1.2.3 Reimbursement Restrictions On Patented Drugs 201
4.1.3 Merger And Acquisition Deals Landscape For Cardiovascular Therapeutics, 2009-2010212
4.2 Respiratory Disease Therapeutics231
4.2.1 Drivers For Respiratory Therapeutics Market241
4.2.1.1 Increase In Aging Population 251
4.2.1.2 Increase In The Incidence Rates For Respiratory Disorders 251
4.2.1.3 Increase In The Diagnosis Rate Of Patients Has Lead To Market Growth251
4.2.1.4 Increase In Awareness Levels Of Disease Progression And Etiology 251
4.2.2 Restraints For Respiratory Therapeutics Market251
4.2.2.1 Patent Expiries Of Blockbuster Drugs251
4.2.2.2 Serious Side Effects For Certain Drugs Have Lead To Non-Initiation And Non Compliance Of The Therapy251
4.2.2.3 Reimbursement Restrictions On Patented Drugs Has Restricted The Market Growth251
4.2.3 Merger And Acquisition Deals Landscape For Respiratory Therapeutics, 2009-2010261
Musculoskeletal Disorder Therapeutics272
4.3.1 Drivers For Musculoskeletal Therapeutics Market291
4.3.1.1 Steady Increase In The Elderly Population 301
4.3.1.2 High Incidence And Prevalence Rate Of The Musculoskeletal Disorders 301
4.3.1.3 Increase In Obesity Population 301
4.3.2 Restraints For Musculoskeletal Therapeutics Market301
4.3.2.1 Poor Diagnosis Rate Of The Disease Due To Lack Of Advanced Techniques 301
4.3.2.2 Low Affordability Of Patients To Get The Treatment For Musculoskeletal Disorders 301
4.3.2.3 Availability Of Alternative Treatment Options 301
4.3.3 Merger And Acquisition Deals Landscape For Musculoskeletal Therapeutics, 2009-2010302
Oncology Therapeutics322
4.4.1 Drivers For Oncology Therapeutics Market341
4.4.1.1 Steady Increase In The Aging Population341
4.4.1.2 New Innovative Products In The Pipeline341
4.4.1.3 Rapid Uptake Of Targeted Therapies In Key Cancer Indications351
4.4.2 Restraints For Oncology Therapeutics Market351
4.4.2.1 The US Cancer Incidence Moving Towards A Decelerating Growth Rate351
4.4.2.2 Patent Expirations And Entry Of Generics351
4.4.3 Merger And Acquisition Deals Landscape For Oncology, 2009-2010362
4.5 Central Nervous System Therapeutics382
4.5.1 Drivers For CNS Therapeutics Market401
4.5.1.1 Steady Increase In The Aging Population401
4.5.1.2 Stable Increase In Incidence Rates For CNS Disorders401
4.5.1.3 Increase In Awareness Levels Of Disease Progression And Etiology401
4.5.2 Restraints For CNS Therapeutics Market411
4.5.2.1 Patent Expirations And Entry Of Generics Pose A Serious Problem For Primary Manufacturers411
4.5.2.2 Presence Of Serious Side Effects For Certain Classes Of Therapeutic Drugs411
4.5.2.3 Reimbursement Restrictions On Drug Classes For Certain CNS Disorders 411
4.5.3 Merger And Acquisition Deals Landscape For Central Nervous System (CNS) Therapeutics, 2009-2010421
Autoimmune Disease Therapeutics432
4.6.1 Drivers For Autoimmune Therapeutics Market451
4.6.1.1 Increasing Diseased Population 461
4.6.1.2 Increasing Treatment Seeking Behavior Amongst Patients461
4.6.1.3 Increase In The Usage Of Biologics As A Primary Mode Of Therapy461
4.6.2 Restraints for Autoimmune Therapeutics Market461
4.6.2.1 Increase In The Treatment Cost 461
4.6.2.2 Increase In The Entry Of Generics 461
4.6.2.3 Presence Of Serious Side Effects 461
4.6.3 Merger and Acquisition Deals Landscape for Autoimmune Diseases Therapeutics, 2009-2010471
Gastrointestinal Disorder Therapeutics482
4.7.1 Drivers For Gastrointestinal Therapeutics Market501
4.7.1.1 Steady Increase In The Elderly Population501
4.7.1.2 Stable Increase In The Incidence Rates For Gastrointestinal Disorders 501
4.7.1.3 Increase In Awareness Levels Of Disease Progression And Etiology501
4.7.2 Restraints For Gastrointestinal Therapeutics Market511
4.7.2.1 Entry Of Generics Due To Patent Loss Pose A Serious Problem For Primary Manufacturers511
4.7.2.2 Presence Of Serious Side Effects For Certain Classes Of Therapeutic Drugs511
4.7.3 Merger And Acquisition Deals Landscape For Gastrointestinal Therapeutics, 2009-2010512
4.8 Dermatology Therapeutics532
4.8.1 Drivers For Dermatology Therapeutics Market551
4.8.1.1 Steady Increase In The Elderly Population551
4.8.1.2 Stable Increase In The Incidence Rates For Dermatology Diseases551
4.8.1.3 Increase In Awareness Levels Of Disease Progression And Etiology551
Restraints For Dermatology Therapeutics Market561
4.8.2.1 Entries Of Generics Pose A Serious Problem For Primary Manufacturers561
4.8.2.2 Presence Of Serious Side Effects Of Certain Class Of Therapeutic Drugs561
4.8.3 Merger And Acquisition Deals Landscape For Dermatology Therapeutics, 2009-2010561
Opthalmology Therapeutics573
4.9.1 Drivers For Ophthalmology Therapeutics Market601
4.9.1.1 Research And Development Activity601
4.9.1.2 Increase In Awareness Levels Of Disease601
4.9.1.3 Increase In The Prevalence Of Diabetes601
4.9.2 Restraints For Ophthalmology Therapeutics Market601
4.9.2.1 Entry Of Generics Due To Patent Loss601
4.9.2.2 Entry Of Off-Label Products601
4.9.3 Merger And Acquisition Deals Landscape For Ophthalmology Therapeutics, 2009-2010611
Men s Health Therapeutics622
4.10.1 Drivers for Men s Health Market641
4.10.1.1 Steady Increase In Prevalence Population641
4.10.1.2 Launch Of Late Stage Pipeline Drugs641
4.10.1.3 Steady Increase In The Prescription Population641
4.10.2 Restraints for Men s Health Market651
4.10.2.1 Low Treatment Seeking Rate651
4.10.2.2 Low Diagnosis Rate 651
4.10.2.3 Patent Expiry Of A Major Blockbuster Drug651
4.10.3 Merger And Acquisition Deals Landscape For Men s Health Therapeutics, 2009-2010651
Women s Health Therapeutics662
4.11.1 Drivers For Women s Health Market681
4.11.1.1 Introduction Of First In Class Therapies With Better Efficacy681
4.11.1.2 Increase In Aging Population681
4.11.1.3 Increase In Treatment Seeking Population Due To Awareness681
4.11.2 Restraints For Women s Health Market691
4.11.2.1 Availability Of Alternative Treatment Options Such As Yoga, Physiotherapy And Others 691
4.11.2.2 Low Prescription Rate Due To Unclear Etiology691
4.11.3 Merger And Acquisition Deals Landscape For Women s Health Therapeutics, 2009-2010691
Blood Disorders Therapeutics 702
4.12.1 Drivers For Blood Disorders Therapeutics721
4.12.1.1 Increase In The Prevalence Population Particularly In Anemia, In The Top Five Countries In Europe721
4.12.1.2 Rapid Uptake Of Biologics Products Due To Better Efficacy And Safety721
4.12.1.3 Increase In Blood Disorders Causing Conditions Such As Cancer And Cardiovascular Events721
4.12.2 Restraints For Blood Disorders Therapeutics731
4.12.2.1 Patent Expiries Of Major Blockbuster Drugs 731
4.12.2.2 Low Diagnosis Rate As The Contemporary Diagnostic Tools Are Unable To Diagnose The Severe Forms Of Blood Disorders731
4.12.2.3 Sluggish Growth In Annual Cost Of Therapy For Blood Disorders 731
4.12.3 Merger And Acquisition Deals Landscape For Blood Disorders Therapeutics Market, 2009-2010742
4.13 Urological Therapeutics Market762
4.13.1 Drivers For Urology Therapeutics781
4.13.1.1 Steady Increase In The Prevalence Population781
4.13.1.2 Rapid Uptake Of Branded Products Due To Better Efficacy In BPH781
4.13.1.3 Patent Expiry Of Branded Drugs Will Make Them More Affordable781
4.13.2 Restraints for Urology Therapeutics Market791
4.13.2.1 Unwillingness To Seek Medical Help For UI791
4.13.2.2 Patent Expiry Of Major Blockbuster Drugs791
4.13.2.3 Non-Pharmacological Therapy Recommended For BPH And UI791
4.13.3 Merger And Acquisition Deals Landscape For Urology Therapeutics, 2009-2010802
5 Key Promising Drugs In The Pipeline8253
5.1 Cardiovascular Therapeutics821
5.1.1 Tekturna/Rasilez (acute heart failure) 821
5.1.1.1 Overview 821
5.1.1.2 Efficacy821
5.1.1.3 Safety821
5.1.1.4 Clinical Study Details 821
5.1.2 Lixivaptan (acute heart failure)831
5.1.2.1 Overview831
5.1.2.2 Efficacy831
5.1.2.3 Safety831
5.1.2.4 Clinical Study Details 831
5.1.3 Relaxin (acute heart failure)831
5.1.3.1 Overview831
5.1.3.2 Efficacy831
5.1.3.3 Safety841
5.1.3.4 Clinical Study Details841
5.1.4 Cinaciguat (acute heart failure)841
5.1.4.1 Overview841
5.1.4.2 Efficacy841
5.1.4.3 Safety841
5.1.4.4 Clinical Study Details841
5.1.5 Xarelto (atrial fibrillation)851
5.1.5.1 Overview 851
5.1.5.2 Efficacy851
5.1.5.3 Safety851
5.1.5.4 Clinical Study Details 851
5.1.6 Pradaxa (atrial fibrillation)861
5.1.6.1 Overview861
5.1.6.2 Efficacy861
5.1.6.3 Safety861
5.1.6.4 Clinical Study Details 861
5.1.7 Stedicor (atrial fibrillation)861
5.1.7.1 Overview861
5.1.7.2 Efficacy861
5.1.7.3 Safety861
5.1.7.4 Clinical Study Details871
5.1.8 Kynapid (atrial fibrillation)871
5.1.8.1 Overview871
5.1.8.2 Efficacy871
5.1.8.3 Safety881
5.1.8.4 Clinical Study Details881
5.1.9 Edoxaban (atrial fibrillation)881
5.1.9.1 Overview881
5.1.9.2 Efficacy881
5.1.9.3 Safety881
5.1.9.4 Clinical Study Details881
5.2 Respiratory Therapeutics891
5.2.1 Flutiform (fluticasone propionate/formoterol fumarate inhalation aerosol) (asthma)891
5.2.1.1 Overview 891
5.2.1.2 Efficacy891
5.2.1.3 Safety891
5.2.1.4 Clinical Study Details 891
5.2.2 MFF 258 (Mometasone furoate/formoterol fumarate) (asthma)901
5.2.2.1 Overview901
5.2.2.2 Efficacy911
5.2.2.3 Safety911
5.2.2.4 Clinical Study Details 911
5.2.3 Aclidinium bromide (Chronic Obstructive Pulmonary Disease-COPD)911
5.2.3.1 Overview 911
5.2.3.2 Efficacy911
5.2.3.3 Safety911
5.2.3.4 Clinical Study Details 911
5.2.4 GW642444 ( 444) (COPD)921
5.2.4.1 Overview921
5.2.4.2 Efficacy921
5.2.4.3 Safety921
5.2.4.4 Clinical Study Details 921
5.2.5 Iloprost (Pulmonary Arterial Hypertension)931
5.2.5.1 Overview931
5.2.5.2 Efficacy931
5.2.5.3 Safety Profile931
5.2.5.4 Clinical Study Details931
5.2.6 ACT-064992 (Pulmonary Arterial Hypertension)931
5.2.6.1 Overview931
5.2.6.2 Efficacy931
5.2.6.3 Safety Profile931
5.2.6.4 Clinical Study Details931
5.2.7 Denufosol Tetrasodium Inhalation Solution (INS37217) (Cystic Fibrosis)941
5.2.7.1 Overview941
5.2.7.2 Efficacy941
5.2.7.3 Safety 941
5.2.7.4 Clinical Study Details 941
5.2.8 VX-770 (Cystic Fibrosis)951
5.2.8.1 Overview951
5.2.8.2 Efficacy951
5.2.8.3 Safety 951
5.2.8.4 Clinical Study Details 951
5.3 Musculoskeletal Disorder Therapeutics961
5.3.1 Catena/Sovrima (Idebenone) 961
5.3.1.1 Overview 961
5.3.1.2 Efficacy 961
5.3.1.3 Safety 961
5.3.1.4 Clinical Study Details 961
5.3.2 IPlex(TM) (mecasermin rinfabate) 961
5.3.2.1 Overview 961
5.3.2.2 Efficacy 961
5.3.2.3 Safety 961
5.3.2.4 Clinical Study Details 961
5.3.3 CG5503 971
5.3.3.1 Overview 971

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions" Dec 01, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Pharmaceutical-Industry-2010-Yearbook-Therapeutic-Market-Landscape-Key-Pipeline-Drugs-Top-Pharma-Companies-and-Key-Mergers-and-Acquisitions-2115-116>
  
APA:
GBI Research Reports. (2010). Pharmaceutical Industry - 2010 Yearbook - Therapeutic Market Landscape, Key Pipeline Drugs, Top Pharma Companies and Key Mergers and Acquisitions Dec 01, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Pharmaceutical-Industry-2010-Yearbook-Therapeutic-Market-Landscape-Key-Pipeline-Drugs-Top-Pharma-Companies-and-Key-Mergers-and-Acquisitions-2115-116>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.